Elekta
66.85 SEK -0.67%9 investors are following this company
Elekta provides medical technology. The company specializes in the development of clinical solutions for the treatment of cancer and brain diseases. Elekta's treatment system and planning software for radiation therapy and radiation surgery as well as other software systems are used in the healthcare industry to identify and analyze various health conditions. Operations are conducted on a global level, with headquarters in Stockholm.
Revenue
-
EBIT %
-
P/E
19.6
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
EKTA B
Daily low / high price
66.4 / 67.4
SEK
Market cap
25.64B SEK
Turnover
76.46M SEK
Volume
1.1M
Financial calendar
Interim report
24.08.2024
General meeting
05.09.2024
Half year dividend
06.09.2024
Interim report
27.11.2024
Interim report
21.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Fjärde AP-fonden | 9.1 % | 6.7 % |
Laurent Leksell fam och bolag | 5.7 % | 30.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Elekta's Annual Report for 2023/24 available
Elekta to become new issuer in the Swedish commercial paper market
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools